Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model
Rearrangement of the neurotrophic tropomyosin receptor kinase 1 ( ) gene, which encodes tyrosine receptor kinase A (TRK-A), occurs in various cancers, including colon cancer. Although entrectinib is effective in the treatment of central nervous system (CNS) metastases that express fusion proteins, a...
Saved in:
Published in | Clinical cancer research Vol. 24; no. 10; pp. 2357 - 2369 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Association for Cancer Research Inc
15.05.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Rearrangement of the neurotrophic tropomyosin receptor kinase 1 (
) gene, which encodes tyrosine receptor kinase A (TRK-A), occurs in various cancers, including colon cancer. Although entrectinib is effective in the treatment of central nervous system (CNS) metastases that express
fusion proteins, acquired resistance inevitably results in recurrence. The CNS is a sanctuary for targeted drugs; however, the mechanism by which CNS metastases become entrectinib-resistant remains elusive and must be clarified to develop better therapeutics.
The entrectinib-resistant cell line KM12SM-ER was developed by continuous treatment with entrectinib in the brain metastasis-mimicking model inoculated with the entrectinib-sensitive human colon cancer cell line KM12SM, which harbors the
gene fusion. The mechanism of entrectinib resistance in KM12SM-ER cells was examined by next-generation sequencing. Compounds that overcame entrectinib resistance were screened from a library of 122 kinase inhibitors.
KM12SM-ER cells, which showed moderate resistance to entrectinib
, had acquired the G667C mutation in
The kinase inhibitor foretinib inhibited TRK-A phosphorylation and the viability of KM12SM-ER cells bearing the
-G667C mutation
Moreover, foretinib markedly inhibited the progression of entrectinib-refractory KM12SM-ER-derived liver metastases and brain tumors in animal models, predominantly through inhibition of TRK-A phosphorylation.
These results suggest that foretinib may be effective in overcoming entrectinib resistance associated with the
-G667C mutation in
fusion-positive tumors in various organs, including the brain, and provide a rationale for clinical trials of foretinib in cancer patients with entrectinib-resistant tumors harboring the
-G667C mutation, including patients with brain metastases.
. |
---|---|
AbstractList | Rearrangement of the neurotrophic tropomyosin receptor kinase 1 (
) gene, which encodes tyrosine receptor kinase A (TRK-A), occurs in various cancers, including colon cancer. Although entrectinib is effective in the treatment of central nervous system (CNS) metastases that express
fusion proteins, acquired resistance inevitably results in recurrence. The CNS is a sanctuary for targeted drugs; however, the mechanism by which CNS metastases become entrectinib-resistant remains elusive and must be clarified to develop better therapeutics.
The entrectinib-resistant cell line KM12SM-ER was developed by continuous treatment with entrectinib in the brain metastasis-mimicking model inoculated with the entrectinib-sensitive human colon cancer cell line KM12SM, which harbors the
gene fusion. The mechanism of entrectinib resistance in KM12SM-ER cells was examined by next-generation sequencing. Compounds that overcame entrectinib resistance were screened from a library of 122 kinase inhibitors.
KM12SM-ER cells, which showed moderate resistance to entrectinib
, had acquired the G667C mutation in
The kinase inhibitor foretinib inhibited TRK-A phosphorylation and the viability of KM12SM-ER cells bearing the
-G667C mutation
Moreover, foretinib markedly inhibited the progression of entrectinib-refractory KM12SM-ER-derived liver metastases and brain tumors in animal models, predominantly through inhibition of TRK-A phosphorylation.
These results suggest that foretinib may be effective in overcoming entrectinib resistance associated with the
-G667C mutation in
fusion-positive tumors in various organs, including the brain, and provide a rationale for clinical trials of foretinib in cancer patients with entrectinib-resistant tumors harboring the
-G667C mutation, including patients with brain metastases.
. Purpose: Rearrangement of the neurotrophic tropomyosin receptor kinase 1 (NTRK1) gene, which encodes tyrosine receptor kinase A (TRK-A), occurs in various cancers, including colon cancer. Although entrectinib is effective in the treatment of central nervous system (CNS) metastases that express NTRK1 fusion proteins, acquired resistance inevitably results in recurrence. The CNS is a sanctuary for targeted drugs; however, the mechanism by which CNS metastases become entrectinib-resistant remains elusive and must be clarified to develop better therapeutics. Experimental Design: The entrectinib-resistant cell line KM12SM-ER was developed by continuous treatment with entrectinib in the brain metastasis–mimicking model inoculated with the entrectinib-sensitive human colon cancer cell line KM12SM, which harbors the TPM3-NTRK1 gene fusion. The mechanism of entrectinib resistance in KM12SM-ER cells was examined by next-generation sequencing. Compounds that overcame entrectinib resistance were screened from a library of 122 kinase inhibitors. Results: KM12SM-ER cells, which showed moderate resistance to entrectinib in vitro, had acquired the G667C mutation in NTRK1. The kinase inhibitor foretinib inhibited TRK-A phosphorylation and the viability of KM12SM-ER cells bearing the NTRK1-G667C mutation in vitro. Moreover, foretinib markedly inhibited the progression of entrectinib-refractory KM12SM-ER–derived liver metastases and brain tumors in animal models, predominantly through inhibition of TRK-A phosphorylation. Conclusions: These results suggest that foretinib may be effective in overcoming entrectinib resistance associated with the NTRK1-G667C mutation in NTRK1 fusion–positive tumors in various organs, including the brain, and provide a rationale for clinical trials of foretinib in cancer patients with entrectinib-resistant tumors harboring the NTRK1-G667C mutation, including patients with brain metastases. Clin Cancer Res; 24(10); 2357–69. ©2018 AACR. Purpose: Rearrangement of the neurotrophic tropomyosin receptor kinase 1 (NTRK1) gene, which encodes tyrosine receptor kinase A (TRK-A), occurs in various cancers, including colon cancer. Although entrectinib is effective in the treatment of central nervous system (CNS) metastases that express NTRK1 fusion proteins, acquired resistance inevitably results in recurrence. The CNS is a sanctuary for targeted drugs; however, the mechanism by which CNS metastases become entrectinib-resistant remains elusive and must be clarified to develop better therapeutics.Experimental Design: The entrectinib-resistant cell line KM12SM-ER was developed by continuous treatment with entrectinib in the brain metastasis–mimicking model inoculated with the entrectinib-sensitive human colon cancer cell line KM12SM, which harbors the TPM3-NTRK1 gene fusion. The mechanism of entrectinib resistance in KM12SM-ER cells was examined by next-generation sequencing. Compounds that overcame entrectinib resistance were screened from a library of 122 kinase inhibitors.Results: KM12SM-ER cells, which showed moderate resistance to entrectinib in vitro, had acquired the G667C mutation in NTRK1. The kinase inhibitor foretinib inhibited TRK-A phosphorylation and the viability of KM12SM-ER cells bearing the NTRK1-G667C mutation in vitro. Moreover, foretinib markedly inhibited the progression of entrectinib-refractory KM12SM-ER–derived liver metastases and brain tumors in animal models, predominantly through inhibition of TRK-A phosphorylation.Conclusions: These results suggest that foretinib may be effective in overcoming entrectinib resistance associated with the NTRK1-G667C mutation in NTRK1 fusion–positive tumors in various organs, including the brain, and provide a rationale for clinical trials of foretinib in cancer patients with entrectinib-resistant tumors harboring the NTRK1-G667C mutation, including patients with brain metastases. Clin Cancer Res; 24(10); 2357–69. ©2018 AACR. |
Author | Kita, Kenji Wang, Rong Nishiyama, Akihiro Arai, Sachiko Fukuda, Koji Yamada, Tadaaki Takeuchi, Shinji Kinoshita, Takayoshi Yano, Seiji Tanimoto, Azusa Furuya, Noritaka Tange, Shoichiro Tajima, Atsushi |
Author_xml | – sequence: 1 givenname: Akihiro surname: Nishiyama fullname: Nishiyama, Akihiro organization: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan – sequence: 2 givenname: Tadaaki surname: Yamada fullname: Yamada, Tadaaki organization: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 3 givenname: Kenji surname: Kita fullname: Kita, Kenji organization: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan – sequence: 4 givenname: Rong surname: Wang fullname: Wang, Rong organization: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan – sequence: 5 givenname: Sachiko surname: Arai fullname: Arai, Sachiko organization: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan – sequence: 6 givenname: Koji surname: Fukuda fullname: Fukuda, Koji organization: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan – sequence: 7 givenname: Azusa surname: Tanimoto fullname: Tanimoto, Azusa organization: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan – sequence: 8 givenname: Shinji surname: Takeuchi fullname: Takeuchi, Shinji organization: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan – sequence: 9 givenname: Shoichiro surname: Tange fullname: Tange, Shoichiro organization: Department of Bioinformatics and Genomics, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Kanazawa, Japan – sequence: 10 givenname: Atsushi surname: Tajima fullname: Tajima, Atsushi organization: Department of Bioinformatics and Genomics, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Kanazawa, Japan – sequence: 11 givenname: Noritaka surname: Furuya fullname: Furuya, Noritaka organization: Kissei Pharmaceutical, Nagano, Japan – sequence: 12 givenname: Takayoshi surname: Kinoshita fullname: Kinoshita, Takayoshi organization: Graduate School of Science, Osaka Prefecture University, Osaka, Japan – sequence: 13 givenname: Seiji surname: Yano fullname: Yano, Seiji email: syano@staff.kanazawa-u.ac.jp organization: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan. syano@staff.kanazawa-u.ac.jp |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29463555$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkctu1DAUQC1URF98AsgSGzYpdvxIsixRpyA6tBoNa8uxb1RXE7vYTlH_ox-Mo5myYHUfOvchnVN05IMHhD5QckGpaL9Q0rQV4ay-6PtNRZuKypq9QSdUiKZitRRHJX9ljtFpSg-EUE4Jf4eO645LJoQ4QS-rECE77wZ8-wTRhAkSvvI5gtl3N5BcytobwJcpBeN0Bov_uHyP8z3gn9vND4qvpWx6vJ6zzi547Pyhv5pTqau7kFx2T4C38xQi7mG3Swuk8deoS1xD1uVGOYTXwcLuHL0d9S7B-0M8Q79WV9v-W3Vze_29v7ypDGcyV7rRra472QkycBilMLYdqLFGtnoU40g7MVgLhHPDrGwbaRlIqjWDtqOaGHaGPu_3Psbwe4aU1eSSKd9pD2FOqiakoXXNmCjop__QhzBHX74rFGt5xyjnhRJ7ysSQUoRRPUY36fisKFGLNrUoUYsSVbQp2qhFW5n7eNg-DxPYf1OvnthfV_WVOw |
CitedBy_id | crossref_primary_10_1016_j_ejmech_2018_10_023 crossref_primary_10_1007_s00018_023_04729_4 crossref_primary_10_1186_s12882_022_03001_4 crossref_primary_10_3390_molecules27196500 crossref_primary_10_5306_wjco_v13_i2_135 crossref_primary_10_1038_s42003_020_01508_w crossref_primary_10_2174_1568026619666190620155613 crossref_primary_10_1016_j_prp_2019_152572 crossref_primary_10_3389_fcell_2021_689727 crossref_primary_10_1016_S1470_2045_19_30690_4 crossref_primary_10_1016_j_apsb_2023_11_010 crossref_primary_10_1111_cas_14593 crossref_primary_10_1200_PO_18_00183 crossref_primary_10_3390_cancers10040105 crossref_primary_10_3390_molecules27154893 crossref_primary_10_1016_j_apsb_2020_05_004 crossref_primary_10_3389_fcell_2021_654103 crossref_primary_10_1111_cas_15354 crossref_primary_10_1016_j_jtho_2020_01_001 crossref_primary_10_1038_s41467_021_21396_w crossref_primary_10_3389_fonc_2022_864666 crossref_primary_10_1016_j_ejmech_2023_115953 |
Cites_doi | 10.1038/319743a0 10.1021/acschembio.6b00709 10.1002/(SICI)1097-0215(19990315)80:6<842::AID-IJC7>3.0.CO;2-Z 10.1007/s11845-015-1272-y 10.1002/(SICI)1099-1492(199805)11:3<93::AID-NBM520>3.0.CO;2-H 10.1371/journal.pone.0091940 10.1158/2159-8290.CD-16-1237 10.1158/1535-7163.MCT-16-0522 10.1016/j.tips.2015.04.005 10.1038/ncomms4116 10.1186/gb-2013-14-4-r36 10.1038/nbt.1754 10.1158/0008-5472.CAN-13-3629 10.1158/2159-8290.CD-17-0507 10.1016/S2213-2600(16)30322-8 10.1158/1535-7163.MCT-14-0274 10.1158/1535-7163.MCT-15-0758 10.1517/13543784.2013.812630 10.1038/nm.3729 10.1016/j.canlet.2015.05.013 10.1002/ijc.29858 10.1097/01.JTO.0000473485.38553.f0 10.1021/acs.jmedchem.6b00064 10.1002/cncr.21033 10.1016/j.canlet.2014.04.019 10.1371/journal.pone.0054014 10.1016/j.canlet.2013.07.007 10.1111/cas.12600 10.1101/011650 10.1158/1078-0432.CCR-06-1570 10.1158/2159-8290.CD-15-0940 10.1158/1078-0432.CCR-10-0574 10.4161/cbt.22255 10.1038/nm.3352 10.1158/1078-0432.CCR-09-0694 |
ContentType | Journal Article |
Copyright | 2018 American Association for Cancer Research. Copyright American Association for Cancer Research Inc May 15, 2018 |
Copyright_xml | – notice: 2018 American Association for Cancer Research. – notice: Copyright American Association for Cancer Research Inc May 15, 2018 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 7T5 7TO 7U9 8FD FR3 H94 P64 7X8 |
DOI | 10.1158/1078-0432.CCR-17-1623 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts Biotechnology Research Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef Virology and AIDS Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 |
EndPage | 2369 |
ExternalDocumentID | 10_1158_1078_0432_CCR_17_1623 29463555 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 476 53G 5GY 5RE 5VS 6J9 ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO NPM OK1 P0W P2P QTD RCR RHF RHI RNS SJN TR2 W2D W8F WOQ YKV AAYXX CITATION 7QO 7T5 7TO 7U9 8FD FR3 H94 P64 7X8 |
ID | FETCH-LOGICAL-c436t-a7a8a296950b4ef65cd8b1cdc68af5ff195bdde044c3d6876d3e61aa3e891a0c3 |
ISSN | 1078-0432 |
IngestDate | Fri Oct 25 06:47:43 EDT 2024 Thu Oct 10 22:06:34 EDT 2024 Thu Nov 21 22:45:32 EST 2024 Sat Sep 28 08:38:05 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
License | 2018 American Association for Cancer Research. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c436t-a7a8a296950b4ef65cd8b1cdc68af5ff195bdde044c3d6876d3e61aa3e891a0c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://clincancerres.aacrjournals.org/content/clincanres/24/10/2357.full.pdf |
PMID | 29463555 |
PQID | 2038493144 |
PQPubID | 2046235 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2007122335 proquest_journals_2038493144 crossref_primary_10_1158_1078_0432_CCR_17_1623 pubmed_primary_29463555 |
PublicationCentury | 2000 |
PublicationDate | 2018-05-15 20180515 |
PublicationDateYYYYMMDD | 2018-05-15 |
PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Philadelphia |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2018 |
Publisher | American Association for Cancer Research Inc |
Publisher_xml | – name: American Association for Cancer Research Inc |
References | Nanjo (2022061100462916700_bib14) 2017; 16 Tevlin (2022061100462916700_bib18) 2015; 184 Wiesner (2022061100462916700_bib3) 2014; 5 Shah (2022061100462916700_bib29) 2013; 8 Eder (2022061100462916700_bib31) 2010; 16 Martin-Zanca (2022061100462916700_bib1) 1986; 319 Zheng (2022061100462916700_bib17) 2014; 20 Vaishnavi (2022061100462916700_bib7) 2013; 19 Russo (2022061100462916700_bib11) 2016; 6 Morikawa (2022061100462916700_bib19) 1988; 48 Kodama (2022061100462916700_bib36) 2014; 13 Ardini (2022061100462916700_bib9) 2016; 15 Omuro (2022061100462916700_bib12) 2005; 103 Heinzlmeir (2022061100462916700_bib27) 2016; 11 Nanjo (2022061100462916700_bib23) 2015; 106 Kim (2022061100462916700_bib20) 2013; 14 Menichincheri (2022061100462916700_bib28) 2016; 59 Chun (2022061100462916700_bib13) 2012; 13 Robinson (2022061100462916700_bib21) 2011; 29 Takeuchi (2022061100462916700_bib25) 2016; 138 Drilon (2022061100462916700_bib33) 2017; 7 Sartore-Bianchi (2022061100462916700_bib39) 2015; 108 Farago (2022061100462916700_bib5) 2015; 10 Daniel (2022061100462916700_bib22) 2014 Rolfo (2022061100462916700_bib30) 2013; 22 Mross (2022061100462916700_bib32) 2010; 16 Drilon (2022061100462916700_bib10) 2017; 7 Okamoto (2022061100462916700_bib37) 2013; 340 Beimfohr (2022061100462916700_bib4) 1999; 80 Kim (2022061100462916700_bib6) 2014; 9 Zhang (2022061100462916700_bib15) 2014; 351 Balak (2022061100462916700_bib34) 2006; 12 Yoh (2022061100462916700_bib38) 2017; 5 Yano (2022061100462916700_bib16) 2000; 60 Creancier (2022061100462916700_bib2) 2015; 365 Wong (2022061100462916700_bib8) 2015; 108 Moreno (2022061100462916700_bib24) 1998; 11 Wu (2022061100462916700_bib26) 2015; 36 Faria (2022061100462916700_bib35) 2015; 75 |
References_xml | – volume: 319 start-page: 743 year: 1986 ident: 2022061100462916700_bib1 article-title: A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences publication-title: Nature doi: 10.1038/319743a0 contributor: fullname: Martin-Zanca – volume: 11 start-page: 3400 year: 2016 ident: 2022061100462916700_bib27 article-title: Chemical proteomics and structural biology define EPHA2 inhibition by clinical kinase drugs publication-title: ACS Chem Biol doi: 10.1021/acschembio.6b00709 contributor: fullname: Heinzlmeir – volume: 80 start-page: 842 year: 1999 ident: 2022061100462916700_bib4 article-title: NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19990315)80:6<842::AID-IJC7>3.0.CO;2-Z contributor: fullname: Beimfohr – volume: 184 start-page: 673 year: 2015 ident: 2022061100462916700_bib18 article-title: Brain metastasis from colorectal carcinoma: a single cancer centre experience publication-title: Ir J Med Sci doi: 10.1007/s11845-015-1272-y contributor: fullname: Tevlin – volume: 11 start-page: 93 year: 1998 ident: 2022061100462916700_bib24 article-title: 1H MRS markers of tumor growth in intrasplenic tumors and liver metastasis induced by injection of HT-29 cells in nude mice spleen publication-title: NMR Biomed doi: 10.1002/(SICI)1099-1492(199805)11:3<93::AID-NBM520>3.0.CO;2-H contributor: fullname: Moreno – volume: 9 start-page: e91940 year: 2014 ident: 2022061100462916700_bib6 article-title: NTRK1 fusion in glioblastoma multiforme publication-title: PLoS One doi: 10.1371/journal.pone.0091940 contributor: fullname: Kim – volume: 7 start-page: 400 year: 2017 ident: 2022061100462916700_bib10 article-title: Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK Inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-16-1237 contributor: fullname: Drilon – volume: 16 start-page: 506 year: 2017 ident: 2022061100462916700_bib14 article-title: MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-16-0522 contributor: fullname: Nanjo – volume: 108 start-page: djv307 year: 2015 ident: 2022061100462916700_bib8 article-title: Evaluation of a congenital infantile fibrosarcoma by comprehensive genomic profiling reveals an LMNA-NTRK1 gene fusion responsive to crizotinib publication-title: J Natl Cancer Inst contributor: fullname: Wong – volume: 36 start-page: 422 year: 2015 ident: 2022061100462916700_bib26 article-title: FDA-approved small-molecule kinase inhibitors publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2015.04.005 contributor: fullname: Wu – volume: 5 start-page: 3116 year: 2014 ident: 2022061100462916700_bib3 article-title: Kinase fusions are frequent in Spitz tumours and spitzoid melanomas publication-title: Nat Commun doi: 10.1038/ncomms4116 contributor: fullname: Wiesner – volume: 108 start-page: djv306 year: 2015 ident: 2022061100462916700_bib39 article-title: Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer publication-title: J Natl Cancer Inst contributor: fullname: Sartore-Bianchi – volume: 14 start-page: R36 year: 2013 ident: 2022061100462916700_bib20 article-title: TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions publication-title: Genome Biol doi: 10.1186/gb-2013-14-4-r36 contributor: fullname: Kim – volume: 29 start-page: 24 year: 2011 ident: 2022061100462916700_bib21 article-title: Integrative genomics viewer publication-title: Nat Biotechnol doi: 10.1038/nbt.1754 contributor: fullname: Robinson – volume: 75 start-page: 134 year: 2015 ident: 2022061100462916700_bib35 article-title: Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-3629 contributor: fullname: Faria – volume: 7 start-page: 963 year: 2017 ident: 2022061100462916700_bib33 article-title: A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0507 contributor: fullname: Drilon – volume: 5 start-page: 42 year: 2017 ident: 2022061100462916700_bib38 article-title: Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(16)30322-8 contributor: fullname: Yoh – volume: 13 start-page: 2910 year: 2014 ident: 2022061100462916700_bib36 article-title: Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-14-0274 contributor: fullname: Kodama – volume: 15 start-page: 628 year: 2016 ident: 2022061100462916700_bib9 article-title: Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-15-0758 contributor: fullname: Ardini – volume: 22 start-page: 1081 year: 2013 ident: 2022061100462916700_bib30 article-title: BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer publication-title: Expert Opin Investig Drugs doi: 10.1517/13543784.2013.812630 contributor: fullname: Rolfo – volume: 20 start-page: 1479 year: 2014 ident: 2022061100462916700_bib17 article-title: Anchored multiplex PCR for targeted next-generation sequencing publication-title: Nat Med doi: 10.1038/nm.3729 contributor: fullname: Zheng – volume: 365 start-page: 107 year: 2015 ident: 2022061100462916700_bib2 article-title: Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma publication-title: Cancer Lett doi: 10.1016/j.canlet.2015.05.013 contributor: fullname: Creancier – volume: 138 start-page: 1281 year: 2016 ident: 2022061100462916700_bib25 article-title: Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer publication-title: Int J Cancer doi: 10.1002/ijc.29858 contributor: fullname: Takeuchi – volume: 10 start-page: 1670 year: 2015 ident: 2022061100462916700_bib5 article-title: Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer publication-title: J Thorac Oncol doi: 10.1097/01.JTO.0000473485.38553.f0 contributor: fullname: Farago – volume: 59 start-page: 3392 year: 2016 ident: 2022061100462916700_bib28 article-title: Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor publication-title: J Med Chem doi: 10.1021/acs.jmedchem.6b00064 contributor: fullname: Menichincheri – volume: 103 start-page: 2344 year: 2005 ident: 2022061100462916700_bib12 article-title: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib publication-title: Cancer doi: 10.1002/cncr.21033 contributor: fullname: Omuro – volume: 351 start-page: 6 year: 2014 ident: 2022061100462916700_bib15 article-title: Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer publication-title: Cancer Lett doi: 10.1016/j.canlet.2014.04.019 contributor: fullname: Zhang – volume: 8 start-page: e54014 year: 2013 ident: 2022061100462916700_bib29 article-title: Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer publication-title: PLoS One doi: 10.1371/journal.pone.0054014 contributor: fullname: Shah – volume: 340 start-page: 97 year: 2013 ident: 2022061100462916700_bib37 article-title: Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models publication-title: Cancer Lett doi: 10.1016/j.canlet.2013.07.007 contributor: fullname: Okamoto – volume: 106 start-page: 244 year: 2015 ident: 2022061100462916700_bib23 article-title: In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line publication-title: Cancer Sci doi: 10.1111/cas.12600 contributor: fullname: Nanjo – year: 2014 ident: 2022061100462916700_bib22 article-title: FusionCatcher - a tool for finding somatic fusion genes in paired-end RNA-sequencing data publication-title: bioRxiv doi: 10.1101/011650 contributor: fullname: Daniel – volume: 12 start-page: 6494 year: 2006 ident: 2022061100462916700_bib34 article-title: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-1570 contributor: fullname: Balak – volume: 6 start-page: 36 year: 2016 ident: 2022061100462916700_bib11 article-title: Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-0940 contributor: fullname: Russo – volume: 48 start-page: 6863 year: 1988 ident: 2022061100462916700_bib19 article-title: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice publication-title: Cancer Res contributor: fullname: Morikawa – volume: 16 start-page: 3507 year: 2010 ident: 2022061100462916700_bib31 article-title: A phase 1 study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-0574 contributor: fullname: Eder – volume: 60 start-page: 4959 year: 2000 ident: 2022061100462916700_bib16 article-title: Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis publication-title: Cancer Res contributor: fullname: Yano – volume: 13 start-page: 1376 year: 2012 ident: 2022061100462916700_bib13 article-title: Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? publication-title: Cancer Biol Ther doi: 10.4161/cbt.22255 contributor: fullname: Chun – volume: 19 start-page: 1469 year: 2013 ident: 2022061100462916700_bib7 article-title: Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer publication-title: Nat Med doi: 10.1038/nm.3352 contributor: fullname: Vaishnavi – volume: 16 start-page: 311 year: 2010 ident: 2022061100462916700_bib32 article-title: Phase 1 study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-0694 contributor: fullname: Mross |
SSID | ssj0014104 |
Score | 2.440587 |
Snippet | Rearrangement of the neurotrophic tropomyosin receptor kinase 1 (
) gene, which encodes tyrosine receptor kinase A (TRK-A), occurs in various cancers,... Purpose: Rearrangement of the neurotrophic tropomyosin receptor kinase 1 (NTRK1) gene, which encodes tyrosine receptor kinase A (TRK-A), occurs in various... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 2357 |
SubjectTerms | Amino Acid Substitution Anilides - chemistry Anilides - pharmacology Animal models Animals Benzamides - chemistry Benzamides - pharmacology Brain Brain Neoplasms - genetics Brain Neoplasms - pathology Brain tumors Cancer Cell Line, Tumor Cell Survival - drug effects Cell Survival - genetics Central nervous system Clinical trials Colon Colon cancer Colorectal cancer Disease Models, Animal Dose-Response Relationship, Drug Drug Resistance, Neoplasm - drug effects Enzyme inhibitors Experimental design Gene fusion Gene rearrangement Heterografts Humans Indazoles - chemistry Indazoles - pharmacology Liver Medical research Metastases Metastasis Mice Mimicry Models, Molecular Mutation NTRK1 gene Oncogene Proteins, Fusion - genetics Organs Patients Phosphorylation Proteins Quinolines - chemistry Quinolines - pharmacology Receptor, trkA - chemistry Receptor, trkA - genetics Structure-Activity Relationship Tropomyosin Tumor cells Tumors Tyrosine Viability |
Title | Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29463555 https://www.proquest.com/docview/2038493144 https://search.proquest.com/docview/2007122335 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiEuiDeFBRmJW9TSxM7ruAotC7vdRVUq9hbZqasNdFPUJkhw4j8g8ee48UuYcZxHxYKAi1VNI9vK92U8Hs-MCXnGlJJLzPxl7nI04I5wB8KH74r5XEoJO2guMFF4euIdzvnrM_es1_veiVoqCzlMP1-aV_I_qIIMcMUs2X9AtukUBPAb8IUWEIb2rzCe6BzEPJPWKcwdRlBba4yFKtNKOlNbNA_x261hqKPNdWxjPDuyrZee50fWtDRhh1lu5JMSHWl1MAR7o6O7PiorLi_WGytSq5UOpRVAD5HhiU8hYCysb4L3q626Vm9Up1-mOJeNZSoMtZ5odIR9EhfCOnifnWebdaOLQLYQVgwNWLptvEAhMKHoXSN5a7zes7VZiI0fww7wCL7K5OykDoBO69BSR1pG1czqQMTd-FDYvEJH3LhIldHhLuhNp7qColbyVaJ2TeZRV2WzqkK2Wf4dVl0d8-vS4gbay2EGHEbRbAArvO1V-dK7pbxPTpPJ_Pg4icdn8RVyFas04sUOL14dNUdc3NZ3WzYdmvQyGOb5pYPsGk6_2Q1pqyi-SW6Y7Qw9qLh5i_RUfptcm5qAjTvkW0NR2lCUdihKW4rSlqIUKUqBolRTkWqK0pqiNMuNvKLojy9fa3JSTU6qyYmPCarJSVtyUk3Ou2Q-GcfR4cBcBTJIOfMK0B8iEE7ohe5IcrX0sKSFtNNF6gVi6S6XduhKWKhHnKds4cEKv2DKs4VgKghtMUrZPbKXr3P1gFAHjGAufT_0FpIHdgoGeiq4kmnKZBAu7D4Z1u85-VBVfEn0TtkNEgQmQWASACax_QSB6ZP9Go3EKIdt4oxYwENmc94nT5u_QXXjeZzI1brEZ8C-B_OcuX1yv0KxGdEJOW4F3Id_7vwRud5-S_tkr9iU6jFYyYV8otn2Eyj1vgE |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Foretinib+Overcomes+Entrectinib+Resistance+Associated+with+the+NTRK1+G667C+Mutation+in+NTRK1+Fusion%E2%80%93Positive+Tumor+Cells+in+a+Brain+Metastasis+Model&rft.jtitle=Clinical+cancer+research&rft.au=Nishiyama+Akihiro&rft.au=Yamada+Tadaaki&rft.au=Kita+Kenji&rft.au=Wang%2C+Rong&rft.date=2018-05-15&rft.pub=American+Association+for+Cancer+Research+Inc&rft.issn=1078-0432&rft.eissn=1557-3265&rft.volume=24&rft.issue=10&rft.spage=2357&rft.epage=2369&rft_id=info:doi/10.1158%2F1078-0432.CCR-17-1623&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |